Macular Edema: Causes, Symptoms, Treatment and Integrative Support

Macular edema is swelling of the macula, the small central part of the retina that you use for reading and recognizing faces. Fluid leaks from blood vessels and collects in the retina^1,2. It is not a disease on its own but the result of another condition: most often diabetes, and also blocked retinal veins, inflammation inside the eye (uveitis), eye surgery, wet macular degeneration and some medicines^1,3. It blurs or distorts central vision¹. An OCT scan of the retina confirms it^1,4. Treatment depends on the cause and can include eye injections, steroid implants, anti-inflammatory eye drops, treating the inflammation, or changing a medicine^1,5. The swelling often settles with treatment, but it can come back, and swelling that does not clear can harm vision for good^6,7.

This page explains what macular edema is, its causes and how common each one is, the symptoms and the warning signs that need prompt care, and how it is diagnosed. It then sets out treatment cause by cause, answers whether macular edema can be reversed or go away on its own, lists what is in clinical trials, and ends with where integrative care can and cannot fit alongside your eye doctor.

Macular edema at a glance

On this page

• What is macular edema?
• How common is it?
• Symptoms
• Diagnosis
• Treatment by cause
• Can it be reversed?
• New treatments in clinical trials
• Living with macular edema
• Where integrative care fits
• Outlook
• Frequently asked questions
• Sources

What is macular edema?

The macula sits in the center of the retina, the light-sensitive layer at the back of the eye. It gives you sharp central and color vision⁸. Tiny blood vessels supply it. When those vessels leak, fluid collects in the macula and it swells. The swollen retina cannot focus images sharply, so central vision blurs^1,2. Sometimes the fluid forms small cyst-like pockets, which is called cystoid macular edema^14,8. The thicker the swelling, the worse vision tends to be¹⁵.

Macular edema is not the same as macular degeneration. Wet macular degeneration is one of the conditions that can cause it¹. Central serous chorioretinopathy, in which fluid builds up under the retina, is a separate condition with its own treatments, although some experts list it as a cause of macular edema^16,17,2.

Common causes

Some conditions look like macular edema on a scan but do not leak: high-dose niacin (vitamin B3) can cause cyst-like changes (in a reported case, they cleared after the niacin was stopped), and macular telangiectasia type 2 causes small cavities rather than leakage^27,28.

How common is macular edema?

There is no single figure for macular edema from all causes^1,3. By cause:

• Diabetes: about 3.8% of US adults with diabetes aged 40 and over, or about 746,000 people, had diabetic macular edema in a national survey in 2005 to 2008²⁹. Over time, about 1 in 15 people with diabetes develop it¹⁸.
• Retinal vein occlusion: about 28 million people worldwide had a vein occlusion in 2015³⁰. Macular edema is a leading cause of vision loss in vein occlusion^31,32.
• Uveitis: a third of people seen at a Dutch eye clinic for uveitis had cystoid macular edema, and it was a leading cause of blindness from uveitis^33,34.
• After cataract surgery: in a large UK study, about 1 in 100 eyes with no added risk (1.17%) was diagnosed with swelling after routine surgery²⁶. Swelling found on OCT scans, often mild and without symptoms, is more common: 9% to 14% of eyes^35,36. The risk is higher in people with diabetes, uveitis, a past vein occlusion, scar tissue on the retina, or a complication during surgery²⁶.
• Retinitis pigmentosa: more than half of patients (59%) in one specialist clinic²⁰.

Symptoms of macular edema

The main symptoms are^1,8:

• blurry central vision, or vision that gets worse over time;
• wavy or bent lines, especially when looking straight ahead;
• objects that look a different size in each eye;
• colors that look dull or faded.

Some people have no symptoms at first, especially if only one eye is affected^8,1.

Signs that need prompt care

Get care right away. Call your eye doctor now or go to an emergency room if you have:

• sudden blurring or loss of vision in one eye, which can be a blocked retinal vein or artery^19,37;
• a red, painful, light-sensitive eye with blurred vision, which can be uveitis³⁸;
• straight lines that suddenly look wavy, which can be wet macular degeneration³⁹;
• pain, more redness, light sensitivity or worse vision after an eye injection or eye surgery, which can be infection⁴⁰;
• new floaters, flashes of light or a dark curtain over part of your vision, which can be a retinal detachment⁴¹.

Call 911 if vision loss comes with weakness or numbness in the face, arm or leg, or trouble speaking. These can be signs of a stroke^42,43.

Tell your surgeon promptly if your vision gets worse in the weeks after cataract surgery¹.

How macular edema is diagnosed

Macular edema is found during a dilated eye exam¹.

• Optical coherence tomography (OCT) is a quick, painless scan that shows the layers of the retina and measures how swollen the macula is. It is the main test for finding and following macular edema^1,4,44.
• Fluorescein angiography uses a dye to photograph the retina's blood vessels and shows where they leak or are blocked¹. OCT angiography shows blood flow without dye but does not show leakage, so it adds to, rather than replaces, the dye test⁴⁵.
• An Amsler grid checks for distortion or missing areas in central vision¹.

Finding the cause matters as much as finding the swelling.

• Vein occlusion: blood pressure, blood sugar and cholesterol are checked; clotting tests may be done in younger people, especially if they have none of the usual risk factors^46,47,48. Routine clotting tests for everyone are not supported⁴⁹. A vein occlusion is linked to a higher risk of stroke and heart disease, so see your physician as well⁵⁰.
• Uveitis: tests look for infection or another disease that can cause it³⁸.
• Medicines: people starting fingolimod need an eye exam at the start, 3 to 4 months later, from time to time while taking it, and any time vision changes⁵.

Macular edema treatment by cause

Treating the condition behind the swelling is the first step¹.

Diabetic macular edema

Anti-VEGF eye injections are the main treatment. In a large US trial, vision improved by about 10 to 13 letters (two to three lines) after a year of injections⁵¹. Steroid implants are also approved for diabetic macular edema^52,53. Managing diabetes helps prevent vision loss¹. See our diabetic macular edema page and the diabetic retinopathy guide.

Retinal vein occlusion

Anti-VEGF injections are now the main treatment³². They block VEGF, the protein that makes vessels leak.

• FDA approvals for macular edema after vein occlusion: ranibizumab (Lucentis) in June 2010; aflibercept (Eylea) in September 2012 for central vein occlusion and October 2014 for branch occlusion; faricimab (Vabysmo) in October 2023, with treatment beyond six months approved in April 2026; and high-dose aflibercept (Eylea HD) in November 2025, given every 8 weeks after the first 3 to 5 monthly doses^{10,54,55,56,12,11,57}. Several lower-cost biosimilar versions of ranibizumab and aflibercept are also approved for it⁵⁸.
• Bevacizumab (Avastin) is used off-label. In people with a central vein occlusion, a US trial found it worked as well as aflibercept at 6 months; in a UK trial its results compared with ranibizumab over 2 years were inconclusive^59,60.
• Brolucizumab (Beovu) is not approved for vein occlusion; its trials were stopped because of inflammation and blocked vessels in the eye^61,62.
• Results: in the main trials, vision improved by an average of about 15 to 18 letters, about 3 lines on the eye chart, at 6 months, much more than with sham (fake) injections. For example, in branch vein occlusion it improved by 18.3 letters with ranibizumab against 7.3 with sham^63,64,65. Faricimab worked as well as aflibercept, at about 17 letters⁶⁶.
• How often: injections are usually monthly at first, then less often⁴⁰. In central vein occlusion, people had 10 to 12 injections over 2 years in a UK trial⁶⁰, and in a US trial two-thirds still needed at least one treatment in the fifth year⁶⁷.

Steroid implant. The dexamethasone implant (Ozurdex) was approved for macular edema after vein occlusion in June 2009^10,68. It is mostly used when injections do not work well enough or are not suitable³². Over a year, cataract developed or worsened in about 3 in 10 eyes that had two implants, and it can raise eye pressure^69,70,52.

Laser. Grid laser can help macular edema after branch vein occlusion and was the standard before injections, but it is used much less now^71,32. In central vein occlusion it reduced swelling but did not improve vision⁷². Panretinal laser is used if abnormal new vessels grow after a severe central vein occlusion^19,73.

Follow-up matters. Up to a third of milder central vein occlusions become the severe, poorly perfused type within 3 years, and that type can lead to painful high pressure in the eye (neovascular glaucoma)^74,75. Keep every follow-up visit, even if your vision feels stable^19,75.

Your general health. A vein occlusion is a sign of blood vessel disease. Managing blood pressure, diabetes and cholesterol is part of care^46,48,76.

Uveitic macular edema

The first step is to control the inflammation inside the eye^77,38.

• Steroid injections and implants work best in trials. In the MERIT trial, a dexamethasone implant reduced swelling by 35% at 12 weeks, against 22% with ranibizumab and 11% with methotrexate, and only the implant improved vision. It raised eye pressure more often^78,79. In the POINT trial, steroid injected into the eye worked better than steroid injected around it⁸⁰.
• Triamcinolone injected into the eye wall (suprachoroidal Xipere), approved in October 2021, is the only US product labelled specifically for macular edema with uveitis. In its trial, 47% of people gained 3 lines of vision, against 16% with a sham (fake) procedure^81,82.
• Treatments for the uveitis itself, such as the dexamethasone implant (approved in 2010 for non-infectious uveitis at the back of the eye), the fluocinolone implant Iluvien (uveitis added in March 2025) and adalimumab (Humira, approved in 2016 for non-infectious uveitis in the middle or back of the eye, or the whole eye), treat the inflammation but are not labelled for macular edema as such^52,68,53,83.
• Steroids can cause cataract and glaucoma, so regular eye exams are needed³⁸.

After cataract surgery

Swelling after cataract surgery often settles on its own within a few months^9,14.

• Anti-inflammatory eye drops (NSAIDs), usually with steroid drops, are used to prevent and treat it. The evidence is low certainty for prevention and very low for treatment^14,9. In a large European trial in people without diabetes, combining an NSAID drop with a steroid drop gave the lowest rate (1.5%, against 3.6% and 5.1% with either drop alone)⁸⁴. In the US these drops are approved for pain and inflammation after surgery; using them for macular edema is off-label⁸⁵.
• Swelling that lasts can be treated with steroid injections or implants^4,86.
• Glaucoma drops: prostaglandin drops may slightly raise the risk after surgery in some studies but not others^24,87,26. Do not stop glaucoma drops without your eye doctor.

Our page on cystoid macular edema covers this in more detail.

Wet macular degeneration

Anti-VEGF injections are the main treatment⁸⁸. See wet macular degeneration and the macular degeneration guide.

Retinitis pigmentosa

Carbonic anhydrase inhibitors, taken as acetazolamide tablets or dorzolamide eye drops, are the usual first treatment. They are used off-label^89,90. They reduce swelling on scans, but lasting vision gains are limited, and the swelling often comes back^91,92,89.

When a medicine is the cause

The swelling usually improves after the medicine is stopped or changed. With fingolimod, it cleared after stopping the drug in 84% of cases in clinical trials⁹³. The fingolimod label advises considering stopping it if macular edema develops, and the docetaxel label advises stopping it and considering another cancer treatment^5,21. With pioglitazone, some people improved after stopping it²³. Never stop a medicine on your own: talk to the doctor who prescribed it and your eye doctor together.

Surgery

Vitrectomy, an operation to remove the gel inside the eye, may be used when other treatments have not worked¹.

Can macular edema be reversed or go away on its own?

It depends on the cause.

• After cataract surgery, it often goes away on its own within a few months⁹.
• With uveitis, almost all swelling cleared within 7 years with treatment in a large study, mostly in the US, but it came back in 43% of the eyes where it had cleared⁶.
• After a vein occlusion, in a small long-term study of 66 people, the swelling had cleared for good after about 4 years in half of those with a branch occlusion and 44% of those with a central occlusion. Most others with a branch occlusion needed an injection now and then; most others with a central occlusion still needed frequent injections and had poorer vision⁷. Without treatment, swelling cleared within a year in 18% to 41% of branch-occlusion eyes that had it⁹⁴.
• When a medicine is the cause, it usually clears after the medicine is stopped⁹³.

Swelling that does not clear can harm vision for good: in studies, people whose swelling stayed or came back had worse vision^6,7. That is why prompt treatment matters. No supplement or diet has been shown to clear macular edema⁹⁵.

New treatments for macular edema in clinical trials

Several new treatments are being tested. None is approved yet for the uses below. Status is as of 19 October 2026.

Some approaches have failed. Adding a steroid injected into the eye wall to anti-VEGF injections did not help in vein occlusion, and dexamethasone eye drops (OCS-01) failed in diabetic macular edema in 2026^62,99.

Living with macular edema

• Keep your injection and scan appointments. In trials, vision gains faded when visits and treatment became less frequent^65,67.
• Know your numbers. Work with your physician on blood pressure, blood sugar and cholesterol^76,1.
• Tell your doctors about your eyes before starting fingolimod or similar medicines for multiple sclerosis or ulcerative colitis, docetaxel or pioglitazone, and have eye checks as advised^5,21,23.
• Before cataract surgery, tell your surgeon if you have diabetes, uveitis, a past vein occlusion or scar tissue on the retina, which raise the risk²⁶.
• Blood thinners. Some people with a vein occlusion take aspirin or another blood thinner. Do not stop it on your own before injections or surgery; the retina team will advise^{100,101,102,103}.
• Herbs and supplements. Tell your retina team about all of them. Ginkgo, garlic, turmeric and danshen can raise the risk of bleeding, especially with blood thinners^104,105,106.

Where integrative care fits

Netra Eye Institute is an acupuncture and Oriental medicine practice. Nothing we offer replaces eye injections, steroid treatment, eye drops, laser or surgery, and macular edema care stays with your eye doctor or retina specialist. Our role is adjunctive: care that sits alongside theirs, with the evidence explained before you start.

The evidence for integrative approaches in macular edema is weak. No trial has compared acupuncture with sham (fake) acupuncture for any cause of macular edema⁹⁵. Chinese herbal medicines added to injections for vein occlusion have been tested only in small trials, mostly in China, and the largest recent trial, of one formula, found it did not reduce the number of injections^107,108. We found no studies of Ayurveda in macular edema⁹⁵.

Evidence grades describe how sure we can be about the effect on macular edema. None means no studies; very low means small studies without proper comparison groups; low means consistent observational studies or weak trials. These grades are our own reading of the studies.

Acupuncture near the eye carries rare but serious risks, including bleeding behind the eye. Tell any acupuncturist if you take a blood thinner. If you have sudden eye pain, swelling, a bulging eye or vision loss after acupuncture near the eye, go to an emergency room right away^119,120.

What working with Netra looks like. We ask first that an eye doctor has found the cause of the swelling and set a plan for scans and treatment. If your vision changes suddenly, see them first; that comes before anything we do. Then we:

• ask whether you and your physician have a plan for blood pressure, blood sugar and cholesterol, and whether your injection and scan schedule is in place;
• offer acupuncture if you choose it, with its limited evidence explained, and review your blood thinners and other medicines first;
• where appropriate, offer Chinese herbal medicine reviewed against your blood thinners and diabetes medicines;
• never put herbal washes or drops in the eye, and follow your retina specialist's advice around injections and surgery;
• keep your eye doctor informed, and send you back to them quickly if your vision changes.

Netra Restoration Therapy (NRT) is an adjunctive program: it is used only alongside your eye doctor's care, never instead of it. It is not a treatment for macular edema. It does not replace injections, steroid treatment, eye drops, laser or surgery, and it does not clear swelling from the macula. No clinical trial of NRT in macular edema has been published. For more, see our page on Ayurveda and macular edema.

Outlook

The outlook depends on the cause and on how quickly treatment starts.

• After cataract surgery, most swelling settles on its own or with eye drops^9,14.
• After a vein occlusion, injections improve vision by about 3 lines on average, but many people need treatment for years, and gains fade if follow-up lapses^63,67,7. Severe central vein occlusions have a more guarded outlook⁷⁴.
• With uveitis, swelling usually clears with treatment but often returns. Macular edema is a leading cause of blindness in uveitis, so long-term care matters^6,34.
• When a medicine is the cause, the swelling usually clears after it is stopped, though some people keep some vision loss^93,5.

Frequently asked questions

Can macular edema be reversed?

Often, yes. With treatment of the cause, the swelling frequently clears and vision often improves, but it can return, and swelling that does not clear can harm vision for good^7,6.

Can macular edema go away on its own?

Sometimes. Swelling after cataract surgery often settles within a few months, and some swelling after a branch vein occlusion clears without treatment, but it still needs checking^9,94.

Can macular edema be cured?

It depends on the cause. Swelling after surgery or from a medicine is often cured. With diabetes, vein occlusion or uveitis, it is usually managed over years^9,93,67,6.

What causes macular edema?

Most often diabetes. Other causes include retinal vein occlusion, uveitis, eye surgery, wet macular degeneration, retinitis pigmentosa and some medicines^1,3.

Is macular edema the same as macular degeneration?

No. Macular edema is swelling that can have many causes; wet macular degeneration is one of them¹.

Can stress cause macular edema?

We found no studies showing that it does⁹⁵. Stress is linked to a different condition, central serous chorioretinopathy, in which fluid collects under the retina^115,116,16.

Are there eye drops for macular edema?

No eye drop is approved for macular edema in the US. Anti-inflammatory drops are used off-label after cataract surgery, and dorzolamide drops off-label in retinitis pigmentosa^85,89.

Can macular edema cause blindness?

It can cause serious loss of central vision if it is not treated, and it is a leading cause of blindness in uveitis^34,74.

How long does macular edema last after cataract surgery?

It often settles within 4 months. Swelling that lasts longer is called chronic and may need more treatment^9,4.

What medications can cause macular edema?

Fingolimod and similar medicines for multiple sclerosis or ulcerative colitis, docetaxel and paclitaxel, pioglitazone and rosiglitazone, and prostaglandin glaucoma drops in some people after cataract surgery^{5,21,22,23,24}.

Can acupuncture or natural remedies help macular edema?

No good-quality trials show that acupuncture, herbs or supplements clear macular edema^95,108. Netra offers acupuncture only as adjunctive care alongside your eye doctor, with the evidence explained.

Sources

1. National Eye Institute. Macular Edema. Updated August 6, 2025. link
2. Daruich A, et al. Mechanisms of macular edema: Beyond the surface. Prog Retin Eye Res. 2018. link
3. Makri OE, et al. Drug-induced macular edema. Drugs. 2013. link
4. Ferro Desideri L, et al. Incidence, Pathogenesis, Risk Factors, and Treatment of Cystoid Macula Oedema Following Cataract Surgery: A Systematic Review. Diagnostics (Basel). 2025. link
5. Novartis. GILENYA (fingolimod) capsules prescribing information, section 5.4 Macular Edema. Label effective July 22, 2026. link
6. Tomkins-Netzer O, et al. Seven-Year Outcomes of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial and Follow-up Study Results. Ophthalmology. 2021. link
7. Campochiaro PA, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology. 2014. link
8. Cleveland Clinic. Cystoid Macular Edema. Updated October 16, 2023. link
9. Wingert AM, et al. Non-steroidal anti-inflammatory agents for treating cystoid macular edema following cataract surgery. Cochrane Database Syst Rev. 2022. link
10. U.S. Food and Drug Administration, via openFDA. Drugs@FDA approval records: Lucentis (BLA125156), Eylea (BLA125387), Eylea HD (BLA761355), Vabysmo (BLA761235), Ozurdex (NDA022315), Xipere (NDA211950), Iluvien (NDA201923), Humira (BLA125057), Beovu (BLA761125) and ranibizumab, aflibercept and bevacizumab biosimilars. Checked October 19, 2026. link
11. Regeneron. EYLEA HD (aflibercept) injection 8 mg prescribing information. Label effective April 6, 2026. link
12. Genentech. FDA Approves Updated Vabysmo Label to Extend Treatment for Macular Edema Following Retinal Vein Occlusion (RVO) Beyond Six Months (company statement). April 9, 2026. link
13. Roche. Roche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss (press release). October 10, 2026. link
14. Lim BX, et al. Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after cataract surgery. Cochrane Database Syst Rev. 2016. link
15. Kim BY, et al. Optical coherence tomographic patterns of diabetic macular edema. Am J Ophthalmol. 2006. link
16. Lange C, et al. Central Serous Chorioretinopathy: Etiology, Diagnosis, and Treatment. Dtsch Arztebl Int. 2026. link
17. Feenstra HMA, et al. Central serous chorioretinopathy: An evidence-based treatment guideline. Prog Retin Eye Res. 2024. link
18. National Eye Institute. Diabetic Retinopathy. Updated September 11, 2025. link
19. National Eye Institute. Central Retinal Vein Occlusion (CRVO). Updated November 27, 2024. link
20. Liew G, et al. Prevalence of cystoid macular oedema, epiretinal membrane and cataract in retinitis pigmentosa. Br J Ophthalmol. 2019. link
21. Hospira. Docetaxel Injection prescribing information, section 5.10 Eye Disorders. Label effective January 20, 2025. link
22. Abraxis BioScience. ABRAXANE (paclitaxel protein-bound particles) prescribing information. Label effective October 31, 2022. link
23. Takeda. ACTOS (pioglitazone) tablets prescribing information, section 5.7 Macular Edema. Label effective March 28, 2025. link
24. Viatris Specialty. XALATAN (latanoprost ophthalmic solution) prescribing information, section 5.4 Macular Edema. Label effective May 15, 2023. link
25. Khodor A, et al. Radiation retinopathy: a review. Int Ophthalmol. 2026. link
26. Chu CJ, et al. Risk Factors and Incidence of Macular Edema after Cataract Surgery: A Database Study of 81984 Eyes. Ophthalmology. 2016. link
27. Dajani HM, Lauer AK. Optical coherence tomography findings in niacin maculopathy. Can J Ophthalmol. 2006. link
28. Charbel Issa P, et al. Macular telangiectasia type 2. Prog Retin Eye Res. 2013. link
29. Varma R, et al. Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol. 2014. link
30. Song P, et al. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors. J Glob Health. 2019. link
31. Shalchi Z, et al. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database Syst Rev. 2020. link
32. Temkar S, et al. Retinal vein occlusion-related macular edema: An updated review of current evidence and future directions. Indian J Ophthalmol. 2026. link
33. Lardenoye CW, et al. Impact of macular edema on visual acuity in uveitis. Ophthalmology. 2006. link
34. Rothova A, et al. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996. link
35. Bellocq D, et al. Incidence of Irvine Gass Syndrome after Phacoemulsification with Spectral-Domain Optical Coherence Tomography. Ocul Immunol Inflamm. 2019. link
36. Kim SJ, et al. A method of reporting macular edema after cataract surgery using optical coherence tomography. Retina. 2008. link
37. Bénard-Séguin É, et al. Update on Acute Retinal Arterial Ischemic Disorders. Neurol Clin. 2026. link
38. National Eye Institute. Uveitis. Updated December 4, 2024. link
39. National Eye Institute. Age-Related Macular Degeneration (AMD). Updated June 22, 2021. link
40. National Eye Institute. Injections to Treat Eye Conditions. Updated March 24, 2026. link
41. National Eye Institute. Retinal Detachment. Updated November 5, 2025. link
42. Centers for Disease Control and Prevention. Signs and Symptoms of Stroke. Reviewed May 19, 2026. link
43. National Institute of Neurological Disorders and Stroke. Stroke: Signs and Symptoms. Reviewed July 23, 2026. link
44. Virgili G, et al. Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy. Cochrane Database Syst Rev. 2015. link
45. Mayeda MS, de Carlo Forest TE. Optical coherence tomography angiography in retinal vascular disease: transformative tool or expensive gimmick? Curr Opin Ophthalmol. 2026. link
46. O'Mahoney PR, et al. Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol. 2008. link
47. Yau JW, et al. Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Intern Med J. 2008. link
48. Kuhli-Hattenbach C, et al. [Cardiovascular risk factors, haemostasis and antithrombotic treatment in retinal vessel occlusion]. Ophthalmologie. 2022. link
49. Romiti GF, et al. Inherited and acquired thrombophilia in adults with retinal vascular occlusion: A systematic review and meta-analysis. J Thromb Haemost. 2020. link
50. Wu CY, et al. ASSOCIATION OF RETINAL VEIN OCCLUSION WITH CARDIOVASCULAR EVENTS AND MORTALITY: A Systematic Review and Meta-analysis. Retina. 2019. link
51. Wells JA, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015. link
52. Allergan (AbbVie). OZURDEX (dexamethasone intravitreal implant) prescribing information. Label effective March 11, 2026. link
53. ANI Pharmaceuticals. ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg prescribing information. Label effective January 28, 2026. link
54. Genentech. FDA Approves Lucentis (Ranibizumab Injection) for the Treatment of Macular Edema Following Retinal Vein Occlusion (press release, via BioProcess Online). June 24, 2010. link
55. Regeneron. EYLEA (aflibercept) Injection Receives FDA Approval for Macular Edema Following Retinal Vein Occlusion (RVO) (press release). October 6, 2014. link
56. Genentech. FDA Approves Genentech's Vabysmo for the Treatment of Retinal Vein Occlusion (RVO) (press release). October 26, 2023. link
57. Regeneron. EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications (press release). November 19, 2025. link
58. DailyMed and openFDA. Prescribing information for ranibizumab and aflibercept biosimilars (Byooviz, manufactured by Samsung Bioepis for Harrow Eye; Cimerli; Pavblu; Yesafili; Ahzantive, labeler Valorum Biologics; Eydenzelt; Nufymco, labeler Zydus) and Lytenava. Checked October 19, 2026. Byooviz · Eydenzelt · Nufymco · Lytenava
59. Scott IU, et al. Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial. JAMA. 2017. link
60. Hykin P, et al. Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial. JAMA Ophthalmol. 2019. link
61. Novartis. BEOVU (brolucizumab-dbll) injection prescribing information. Label effective November 3, 2025. link
62. ClinicalTrials.gov records NCT05642312 (MEERKAT), NCT05642325 (SANDCAT), NCT06771271 (DOVETAIL), NCT06996080 (PINNACLE), NCT06990399 (PEAK), NCT04592419 (BEACON), NCT05850520 (QUASAR), NCT05608837 (LEOPARD), NCT05147233 (OPTIMIZE-1), NCT06128369 (OPTIMIZE-2), NCT06431373 (CLARITY), NCT07205887 (Super Tuscan), NCT06664502 (EYE201 phase 1/2), NCT04576689 (RIPPLE-1), NCT05532735 (ANXV), NCT07259928 (NEXUS), NCT07708142 (SMO1), NCT05520177 (SSGJ-601 BRVO), NCT02980874 (SAPPHIRE), NCT03203447 (TOPAZ), NCT03810313 (RAVEN), NCT03802630 (RAPTOR), NCT07218770 (TITAN), NCT05099094 (BD311), NCT05844982 (DRCR Protocol AL), NCT04740905 (BALATON), NCT04740931 (COMINO), NCT02623426 (MERIT). Checked October 20, 2026. NCT05642312 · NCT05642325 · NCT06771271 · NCT06996080 · NCT06990399 · NCT04592419 · NCT05850520 · NCT05608837 · NCT05147233 · NCT06128369 · NCT06431373 · NCT07205887 · NCT06664502 · NCT04576689 · NCT05532735 · NCT07259928 · NCT07708142 · NCT05520177 · NCT02980874 · NCT03203447 · NCT03810313 · NCT03802630 · NCT07218770 · NCT05099094 · NCT05844982 · NCT04740905 · NCT04740931 · NCT02623426 Remigromig: Merck. Merck presents one-year results from the pivotal phase 2b/3 BRUNELLO study evaluating remigromig (MK-3000, formerly EYE103). October 10, 2026. Merck
63. Campochiaro PA, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010. link
64. Brown DM, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010. link
65. Heier JS, et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology. 2014. link
66. Tadayoni R, et al. Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials. Ophthalmology. 2024. link
67. Scott IU, et al. Month 60 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion. Am J Ophthalmol. 2022. link
68. GEN (Genetic Engineering & Biotechnology News). Allergan Gains FDA Approval for Ozurdex to Treat Noninfectious Posterior Uveitis. September 27, 2010. link
69. Haller JA, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011. link
70. Haller JA, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010. link
71. Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984. link
72. Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion: the Central Vein Occlusion Study Group M report. Ophthalmology. 1995. link
73. Central Vein Occlusion Study Group. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion: the Central Vein Occlusion Study Group N report. Ophthalmology. 1995. link
74. McIntosh RL, et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010. link
75. Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol. 1997. link
76. Pagán Escribano J, et al. Position paper on retinal vein occlusion. SEMI-SERV. Rev Clin Esp (Barc). 2025. link
77. Levin MH, et al. Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema. Ophthalmology. 2014. link
78. Multicenter Uveitis Steroid Treatment Trial (MUST) Research Group, et al. Intravitreal Therapy for Uveitic Macular Edema-Ranibizumab versus Methotrexate versus the Dexamethasone Implant: The MERIT Trial Results. Ophthalmology. 2023. link
79. Multicenter Uveitis Steroid Treatment Trial (MUST) Research Group, et al. Macular Edema Ranibizumab versus Intravitreal Anti-inflammatory Therapy Trial: 24-Week Outcomes of Uveitic Macular Edema Re-treatment. Ophthalmology. 2025. link
80. Thorne JE, et al. Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema: The PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial. Ophthalmology. 2019. link
81. Bausch & Lomb. XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use prescribing information. Label effective October 8, 2025. link
82. Yeh S, et al. Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial. Ophthalmology. 2020. link
83. AbbVie. HUMIRA (adalimumab) injection prescribing information. Label effective December 23, 2025. link
84. Wielders LHP, et al. European multicenter trial of the prevention of cystoid macular edema after cataract surgery in nondiabetics: ESCRS PREMED study report 1. J Cataract Refract Surg. 2018. link
85. U.S. Food and Drug Administration, via openFDA and DailyMed. Prescribing information for NSAID eye drops used after cataract surgery (Nevanac, Ilevro, Prolensa, BromSite, Acuvail, ketorolac 0.5%): indications cover pain and inflammation after surgery, and no label names cystoid macular edema. Checked October 20, 2026. link
86. Couret C, et al. Comparison of subconjunctival TRIamcinolone acetonide injection and intravitreal dexamethasone (OZurdex) injection for uveitic and postoperative macular oedema: the TRIOZ study. Br J Ophthalmol. 2025. link
87. Wendel C, et al. Association of Postoperative Topical Prostaglandin Analog or Beta-Blocker Use and Incidence of Pseudophakic Cystoid Macular Edema. J Glaucoma. 2018. link
88. National Eye Institute. Treatments for Wet AMD (Advanced Neovascular AMD). Updated December 5, 2024. link
89. Bakthavatchalam M, et al. Treatment of cystoid macular edema secondary to retinitis pigmentosa: a systematic review. Surv Ophthalmol. 2018. link
90. Heritage Pharmaceuticals (Avet) and Sagent Pharmaceuticals. Acetazolamide tablets and dorzolamide hydrochloride ophthalmic solution prescribing information (indications). Checked October 19, 2026. acetazolamide · dorzolamide
91. Zhao C, et al. The efficacy and safety of oral and topical carbonic anhydrase inhibitors for the treatment of macular edema secondary to retinitis pigmentosa: a systematic review and meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2026. link
92. Yang HA, et al. Comparative efficacy of different treatment modalities in the management of macular oedema in retinitis pigmentosa: a systematic review and network meta-analysis. BMJ Open Ophthalmol. 2026. link
93. Zarbin MA, et al. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology. 2013. link
94. Rogers SL, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010. link
95. PubMed (NCBI E-utilities) and Europe PMC literature searches on acupuncture, Chinese herbal medicine, Ayurveda and supplements for macular edema, retinal vein occlusion and uveitis (queries and hit counts listed in the research file). Run October 19–20, 2026. PubMed · Europe PMC
96. Roche. Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss (press release). October 17, 2025. link
97. Kodiak Sciences. SEC Form 8-K, exhibit 99.1 (DAYBREAK topline results and regulatory plans). September 28, 2026. link
98. Ophthalmology Times. Kodiak Sciences reports positive topline results from BEACON Phase 3 study of tarcocimab in patients with retinal vein occlusion. August 9, 2022. link
99. Oculis. Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema (press release). May 29, 2026. link
100. Valeriani E, et al. Antithrombotic treatment for retinal vein occlusion: a systematic review and meta-analysis. J Thromb Haemost. 2023. link
101. Horn W, Hoerauf H. [Intravitreal injections during anticoagulant treatment]. Klin Monbl Augenheilkd. 2008. link
102. Mason JO 3rd, et al. Comparison of hemorrhagic complications of warfarin and clopidogrel bisulfate in 25-gauge vitrectomy versus a control group. Ophthalmology. 2011. link
103. Ryan A, et al. Maintenance of perioperative antiplatelet and anticoagulant therapy for vitreoretinal surgery. Clin Exp Ophthalmol. 2013. link
104. Hatfield J, et al. Dietary supplements and bleeding. Proc (Bayl Univ Med Cent). 2022. link
105. National Center for Complementary and Integrative Health. Ginkgo. Updated February 2025. link
106. Chan TY. Interaction between warfarin and danshen (Salvia miltiorrhiza). Ann Pharmacother. 2001. link
107. Xiaojuan S, et al. Chinese Herbal Medicine Combined with Intravitreal Antivascular Growth Factor Agents in Treatment of Macular Edema Secondary to Retinal Vein Occlusion: A Systematic Review and Meta-Analysis. J Ophthalmol. 2022. link
108. Hongyan W, et al. Jueling Mingmu decoction combined with ranibizumab for retinal vein occlusion induced macular edema: A randomized controlled clinical trial. Int Ophthalmol. 2025. link
109. Zhu X, et al. Treatment of retinal vein obstruction with acupuncture and Chinese medicinal herbs. J Tradit Chin Med. 2002. link
110. Yang W, et al. [Clinical observation on macular edema treated with treating different diseases with the same acupuncture comprehensive therapy]. Zhongguo Zhen Jiu. 2018. link
111. Yan Y, et al. Significant vision improvement and successful prevention of recurrence by electroacupuncture in hemiretinal vein occlusion combined with macular edema: A case report. Medicine (Baltimore). 2021. link
112. Lu B, Wu X. Effect of Lingqi Huangban granule plus intravitreal ranibizumab on macular edema induced by retinal vein occlusion: a randomized controlled clinical trial. J Tradit Chin Med. 2020. link
113. Belcaro G, et al. Recurrent retinal vein thrombosis: prevention with Aspirin, Pycnogenol®, ticlopidine, or sulodexide. Minerva Cardioangiol. 2019. link
114. Rodriguez P, et al. Recurrence of retinal vein thrombosis with Pycnogenol® or Aspirin® supplementation: a registry study. Panminerva Med. 2015. link
115. Liu B, et al. Risk factors for central serous chorioretinopathy: a systematic review and meta-analysis. Retina. 2016. link
116. Hufnagel HJ, et al. [Stress and other risk factors in central serous chorioretinopathy: a myth?]. Ophthalmologie. 2025. link
117. Nongrem G, et al. Effect of short-term meditation training in central serous chorioretinopathy. Indian J Ophthalmol. 2021. link
118. Özcan D, Karapapak M. Effect of mindfulness-based stress reduction on acute central serous chorioretinopathy: a randomized control trial. Int Ophthalmol. 2024. link
119. Lee SM, et al. Severe Adverse Events of Periocular Acupuncture: A Review of Cases. Korean J Ophthalmol. 2023. link
120. Wong TH, et al. Orbital compartment syndrome after periocular acupuncture: Vision preserved by emergent decompression. Am J Emerg Med. 2026. link